JP2017536114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536114A5 JP2017536114A5 JP2017524014A JP2017524014A JP2017536114A5 JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5 JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5
- Authority
- JP
- Japan
- Prior art keywords
- vnar
- amino acid
- encode
- domain
- codons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 15
- 238000000034 method Methods 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108020004705 Codon Proteins 0.000 claims 7
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 238000003498 protein array Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003700 | 2014-11-03 | ||
| EP14003700.3 | 2014-11-03 | ||
| PCT/EP2015/002086 WO2016070959A1 (en) | 2014-11-03 | 2015-10-21 | Methods for generating bispecific shark variable antibody domains and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536114A JP2017536114A (ja) | 2017-12-07 |
| JP2017536114A5 true JP2017536114A5 (enExample) | 2018-11-29 |
| JP6734271B2 JP6734271B2 (ja) | 2020-08-05 |
Family
ID=51945671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524014A Expired - Fee Related JP6734271B2 (ja) | 2014-11-03 | 2015-10-21 | 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11001640B2 (enExample) |
| EP (1) | EP3215531A1 (enExample) |
| JP (1) | JP6734271B2 (enExample) |
| CN (1) | CN107074961A (enExample) |
| AU (1) | AU2015342264B2 (enExample) |
| CA (1) | CA2966397A1 (enExample) |
| IL (1) | IL252008A0 (enExample) |
| WO (1) | WO2016070959A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3033082A1 (en) * | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| US20200216544A1 (en) * | 2017-08-16 | 2020-07-09 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1 |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12351642B2 (en) | 2018-09-14 | 2025-07-08 | Ossianix, Inc. | TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| CN112301431B (zh) * | 2020-08-12 | 2023-01-31 | 华东理工大学 | 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CN112940120B (zh) * | 2021-05-14 | 2021-08-17 | 深圳海创生物技术有限公司 | 降钙素原单域抗体及其应用和试剂盒 |
| CN118475603A (zh) * | 2021-11-03 | 2024-08-09 | 香港城市大学深圳研究院 | 高亲和力抗EGFP和抗SARS-CoV-2 vNAR单域抗体及其用途 |
| CN115975010B (zh) * | 2022-08-31 | 2026-03-24 | 闽江学院 | 一种十足目虹彩病毒1的单域抗体及其制备方法和应用 |
| CN116143913B (zh) * | 2022-12-30 | 2026-03-27 | 闽江学院 | 一种结合SARS-CoV-2 RBD的鲨鱼源单域抗体及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA010594B1 (ru) | 2001-05-24 | 2008-10-30 | Займодженетикс, Инк. | Слитые белки taci-иммуноглобулина |
| US8337845B2 (en) * | 2010-03-03 | 2012-12-25 | Boehringer Ingelheim International Gmbh | A-beta binding polypeptides |
| AU2011290480B2 (en) * | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| WO2013167883A1 (en) * | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| EP3683312B1 (en) * | 2013-04-23 | 2022-09-07 | Elasmogen Limited | Synthetic library of specific binding molecules |
-
2015
- 2015-10-21 US US15/523,888 patent/US11001640B2/en not_active Expired - Fee Related
- 2015-10-21 AU AU2015342264A patent/AU2015342264B2/en not_active Ceased
- 2015-10-21 CN CN201580059697.2A patent/CN107074961A/zh active Pending
- 2015-10-21 CA CA2966397A patent/CA2966397A1/en not_active Abandoned
- 2015-10-21 EP EP15785053.8A patent/EP3215531A1/en not_active Withdrawn
- 2015-10-21 WO PCT/EP2015/002086 patent/WO2016070959A1/en not_active Ceased
- 2015-10-21 JP JP2017524014A patent/JP6734271B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-27 IL IL252008A patent/IL252008A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017114866A5 (enExample) | ||
| IL275270A (en) | Recombinant scavenger cell surface proteins | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| JP2016029056A5 (enExample) | ||
| JP2016026303A5 (enExample) | ||
| HRP20250850T1 (hr) | Antitijela protiv claudina 18.2 korisna u dijagnozi raka | |
| AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| JP2019500862A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018121657A5 (enExample) | ||
| RU2018137419A (ru) | Связывающиеся с cd38 и pd-l1 молекулы | |
| JP2015529826A5 (enExample) | ||
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| JP2013535191A5 (enExample) | ||
| FI3227342T4 (fi) | Proteiininen heterodimeeri ja sen käyttö | |
| JP2014158485A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2016502843A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| Hudson et al. | Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes | |
| JP2013509878A5 (enExample) | ||
| JP2017522886A5 (enExample) | ||
| JP2017501143A5 (enExample) |